Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tetsu Shinkai

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumorsTomohide Tamura, Hironobu Minami, Yasuhide Yamada, et al.
Translational Lung Cancer Research|July 18, 2020
Open-label, multicenter, randomized phase II study on docetaxel plus bevacizumab or pemetrexed plus bevacizumab for treatment of elderly (aged ≥75 years) patients with previously untreated advanced non-squamous non-small cell lung cancer: TORG1323Toshiyuki Kozuki, Naoyuki Nogami, Osamu Hataji, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2006
Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904)Shinzoh Kudoh, Koji Takeda, Kazuhiko Nakagawa, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Triple combination chemotherapy with cisplatin, docetaxel, and irinotecan for advanced non-small cell lung cancer: a phase I/II trialKatsuyuki Kiura, Nagio Takigawa, Yoshihiko Segawa, et al.
Breast Cancer Research and Treatment|August 20, 2009
Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial GroupKenichi Inoue, Kazuhiko Nakagami, Mitsuhiro Mizutani, et al.
Lung Cancer (Amsterdam, Netherlands)|May 11, 2010
A phase I study of S-1 with concurrent thoracic radiotherapy in elderly patients with localized advanced non-small cell lung cancerNagio Takigawa, Katsuyuki Kiura, Katsuyuki Hotta, et al.
Japanese Journal of Clinical Oncology|January 22, 2021
Prognostic impact of geriatric assessment in elderly patients with non-small cell lung cancer: an integrated analysis of two randomized phase III trials (JCOG1115-A)Hiroshi Katayama, Junki Mizusawa, Haruhiko Fukuda, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 19, 2011
Benefits and adverse events among elderly patients receiving concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: analysis of the Okayama Lung Cancer Study Group trial 0007Nagio Takigawa, Katsuyuki Kiura, Yoshihiko Segawa, et al.
The Lancet. Oncology|December 7, 2013
Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 studyKaoru Kubota, Toyoaki Hida, Satoshi Ishikura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2008
Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancerRiichiroh Maruyama, Yutaka Nishiwaki, Tomohide Tamura, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumorsTomohide Tamura, Hironobu Minami, Yasuhide Yamada, et al.
Translational Lung Cancer Research|July 18, 2020
Open-label, multicenter, randomized phase II study on docetaxel plus bevacizumab or pemetrexed plus bevacizumab for treatment of elderly (aged ≥75 years) patients with previously untreated advanced non-squamous non-small cell lung cancer: TORG1323Toshiyuki Kozuki, Naoyuki Nogami, Osamu Hataji, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2006
Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904)Shinzoh Kudoh, Koji Takeda, Kazuhiko Nakagawa, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Triple combination chemotherapy with cisplatin, docetaxel, and irinotecan for advanced non-small cell lung cancer: a phase I/II trialKatsuyuki Kiura, Nagio Takigawa, Yoshihiko Segawa, et al.
Breast Cancer Research and Treatment|August 20, 2009
Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial GroupKenichi Inoue, Kazuhiko Nakagami, Mitsuhiro Mizutani, et al.
Lung Cancer (Amsterdam, Netherlands)|May 11, 2010
A phase I study of S-1 with concurrent thoracic radiotherapy in elderly patients with localized advanced non-small cell lung cancerNagio Takigawa, Katsuyuki Kiura, Katsuyuki Hotta, et al.
Japanese Journal of Clinical Oncology|January 22, 2021
Prognostic impact of geriatric assessment in elderly patients with non-small cell lung cancer: an integrated analysis of two randomized phase III trials (JCOG1115-A)Hiroshi Katayama, Junki Mizusawa, Haruhiko Fukuda, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 19, 2011
Benefits and adverse events among elderly patients receiving concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: analysis of the Okayama Lung Cancer Study Group trial 0007Nagio Takigawa, Katsuyuki Kiura, Yoshihiko Segawa, et al.
The Lancet. Oncology|December 7, 2013
Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 studyKaoru Kubota, Toyoaki Hida, Satoshi Ishikura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2008
Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancerRiichiroh Maruyama, Yutaka Nishiwaki, Tomohide Tamura, et al.
Pageof 5